ADC Therapeutics S.A. (ADCT)
NYSE NYSE Primary Summary
ADCT Stock Plunges on Safety Concerns Despite Positive Lymphoma Data
ADC Therapeutics stock plunges 53% after-hours as investors focus on safety concerns in a phase III DLBCL study of Zynlonta, despite meeting its primary efficacy goal.
ADC Therapeutics SA (ADCT) Discusses Phase III LOTIS-5 Trial Results and Next Steps in DLBCL Transcript
ADC Therapeutics SA (ADCT) Discusses Phase III LOTIS-5 Trial Results and Next Steps in DLBCL Transcript
ADC Therapeutics SA (ADCT) Q1 2026 Earnings Call Transcript
ADC Therapeutics SA (ADCT) Q1 2026 Earnings Call Transcript
ADC Therapeutics S.A. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| CE Curtis Ellergodt Rothschild Investment LLC | 10 | $35 | $12.3 | -$22.7 | -64.86% |
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 20 | $63.2 | $24.5 | -$38.7 | -61.23% |
| BG Bart Gancher Intech Investment Management LLC | 23,988 | $35,432.16 | $29,385.3 | -$6,046.86 | -17.07% |
 Point72 Asset Management LP Point72 Asset Management LP | 3.38M | $9.56M | $4.18M | -$5.38M | -56.29% |
 Joseph Castro Nuveen LLC | 146,258 | $405,702.22 | $180,628.63 | -$225,073.59 | -55.48% |
ADC Therapeutics S.A. (ADCT) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has ADC Therapeutics S.A. ever had a stock split?
ADC Therapeutics S.A. Profile
| Biotechnology Industry | Healthcare Sector | Ameet Mallik CEO | NYSE Exchange | H0036K147 CUSIP |
| CH Country | 188 Employees | - Last Dividend | - Last Split | 16 Mar 1979 IPO Date |
Overview
ADC Therapeutics SA is a biotechnology company that specializes in developing advanced antibody drug conjugate (ADC) therapies aimed at revolutionizing the treatment approaches for patients suffering from hematologic malignancies and solid tumors. Leveraging its proprietary ADC technology platform, the company has successfully brought forward ZYNLONTA, a CD19-directed ADC, which has gained accelerated approval from the U.S. Food and Drug Administration and conditional approval from the European Commission for treating relapsed or refractory diffuse large B-cell lymphoma (DLBCL) following two or more lines of systemic therapy. Headquartered in Epalinges, Switzerland, and founded in 2011, ADC Therapeutics is committed to expanding the reach of ZYNLONTA to international markets and exploring its application in earlier lines of DLBCL and other indolent lymphomas through rigorous clinical trials. The firm's dedication to innovation extends to a robust pipeline of clinical and pre-clinical ADCs aimed at addressing unmet medical needs in oncology.
Products and Services
- ZYNLONTA (loncastuximab tesirine)
As the flagship product, ZYNLONTA is a CD19-directed antibody drug conjugate (ADC) that has been granted accelerated approval by the FDA and conditional approval by the European Commission. It is designated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is actively pursuing the expansion of ZYNLONTA into international markets, and its versatility in treating earlier stages of DLBCL and indolent lymphomas, such as follicular lymphoma (FL) and marginal zone lymphoma (MZL), both as a single agent and in combination, is being evaluated in LOTIS-5, a confirmatory Phase 3 clinical trial, and LOTIS-7, a Phase 1b clinical trial, along with investigator-initiated trials (IITs).
- ADCT-602
Targeting CD-22, ADCT-602 represents a promising investigational ADC in the realm of hematologic malignancies. It is currently being explored in a Phase 1/2 investigator-initiated study for its efficacy in treating relapsed or refractory B-cell acute lymphoblastic leukemia (ALL), marking a significant step in addressing specific leukemias with high unmet medical needs.
- ADCT-601 (mipasetamab uzoptirine)
This ADC targets AXL and is being developed both as a standalone therapy and in combination with other treatments. ADCT-601 is undergoing clinical evaluation for its potential in treating various cancers, including sarcoma, pancreatic cancer, and non-small cell lung cancer (NSCLC), showcasing ADC Therapeutics' commitment to diversifying its therapeutic applications and benefiting a broader patient population.
- Pre-Clinical ADC Pipeline
ADC Therapeutics is also advancing a suite of next-generation investigational ADCs targeting novel antigens such as Claudin-6, NaPi2b, PSMA, and other undisclosed targets. Still in pre-clinical development, these candidates represent the company's forward-looking approach to cancer treatment, aiming to deliver innovative therapies that can effectively target and eliminate tumor cells with reduced toxicity to healthy tissues.
